Faslg Protein Fas Ligand is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Symbol | FASLG |
| Protein Name | Fas Cell Surface Death Receptor Ligand |
| Aliases | FasL, CD95L, APT1LG1 |
| Molecular Weight | 26 kDa (membrane), 17 kDa (soluble) |
| Protein Family | TNF Superfamily |
| Receptor | FAS (CD95) |
| Associated Diseases | AD, PD, ALS, HD, Stroke, Autoimmune Disorders, Cancer |
FASLG (Fas Ligand), also known as FasL or CD95L, is a member of the TNF (Tumor Necrosis Factor) superfamily of cytokines. It is a type II transmembrane protein that binds to FAS (CD95), a death receptor on the cell surface. The FASLG-FAS interaction triggers apoptosis through the extrinsic programmed cell death pathway. In the central nervous system, FASLG plays critical roles in neuronal development, immune privilege, and neuroinflammation. Dysregulation of this pathway contributes to neuronal loss in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions.
FASLG exists in two forms:
FASLG is elevated in AD brain and CSF. The FasL-Fas pathway contributes to:
Therapeutic strategies include Fas receptor blockers and decoy receptors.
FASLG upregulation in PD substantia nigra promotes dopaminergic neuron death. The pathway mediates:
FASLG contributes to motor neuron loss in ALS. Both extrinsic apoptosis and non-apoptotic signaling are involved. Fas receptor deficiency provides neuroprotection in mouse models.
FASLG is increased in HD brain and striatal neurons. Contributes to:
FASLG mediates neuronal death following cerebral ischemia. Blocking the pathway reduces infarct size in experimental models.
Dysregulated FasL contributes to autoimmune tissue damage. Mutations in FASLG cause autoimmune lymphoproliferative syndrome (ALPS).
Tumor cells often express FasL to kill invading T cells (immune evasion). Therapeutic approaches exploit this pathway.
| Approach | Status | Description |
|---|---|---|
| Fas-Fc fusion protein | Preclinical | Decoy receptor |
| Anti-FasL antibodies | Preclinical | Neutralizing antibodies |
| Caspase inhibitors | Clinical | Broad apoptosis blockers |
| Gene therapy | Research | Targeting FasL expression |
The study of Faslg Protein Fas Ligand has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.